Objective. To investigate predictors of response, remission, low disease activity (LDA), damage 3 and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with 4 belimumab. 5 Methods. We retrospectively analysed data of a multicentre cohort of SLE patients receiving 6 intravenous belimumab. Proportion of patients achieving remission, LDA and SLE Responder 7 Index-4 (SRI-4) were evaluated. SLICC damage index (SDI) was calculated yearly. Predictors of 8 outcomes were investigated by multivariate logistic regression. 9 Results. We included 466 active SLE patients from 24 Italian centres: median (range) follow-up 10 18 (1-60) months. SRI-4 was achieved by 49.2%, 61.3%, 69.7%, 69.6% and 66.7% patients at 6, 11 12, 24, 36 and 48 months. Baseline predictors of response at 6 months were SLEDAI-2K≥10 (OR 12 3.14, 95%CI 2.033-4.860) and disease duration≤2 years (OR 1.94, 95%CI 1.078-3.473); at 12 13 months SLEDAI-2K≥10 (OR 3.48, 95%CI 2.004-6.025), SDI=0 (OR 1.74, 95%CI 1.036-2.923); 14 at 24 months SLEDAI-2K≥ 10 (OR 4.25, 95%CI 2.018-8.940), disease duration ≤2 years (OR 15 3.79, 95%CI 1.039-13.52); at 36 months SLEDAI-2K≥10 (OR 14.59, 95%CI 3.54-59.79) and 16 baseline smoking (OR 0.19, 95%CI 0.039-0.69). Patients spending≥25% follow-up in remission 17 (42.9%) or ≥ 50% in LDA (66.0%) accrued significantly less damage (p=0.046 and p=0.007). 18 Baseline SDI=0 independently predicted LDA ≥50% and remission ≥25%; the lower the baseline 19 damage, the higher the probability of remission ≥ 25%. Number of previous flares negatively 20 predicted belimumab discontinuation due to inefficacy (p= 0.009) 21 Conclusions. The early use of belimumab in patients with active SLE and low baseline damage 22 predicts favourable outcomes in a real-life setting.

Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting / Gatto, Mariele; Saccon, Francesca; Zen, Margherita; Regola, Francesca; Fredi, Micaela; Andreoli, Laura; Tincani, Angela; Urban, Maria Letizia; Emmi, Giacomo; Ceccarelli, Fulvia; Conti, Fabrizio; Bortoluzzi, Alessandra; Govoni, Marcello; Tani, Chiara; Mosca, Marta; Ubiali, Tania; Gerosa, Maria; Bozzolo, Enrica; Canti, Valentina; Cardinaletti, Paolo; Gabrielli, Armando; Tanti, Giacomo; Gremese, Elisa; De Marchi, Ginevra; De Vita, Salvatore; Fasano, Serena; Ciccia, Francesco; Pazzola, Giulia; Salvarani, Carlo; Negrini, Simone; Puppo, Francesco; Di Matteo, Andrea; De Angelis, Rossella; Orsolini, Giovanni; Rossini, Maurizio; Faggioli, Paola; Laria, Antonella; Piga, Matteo; Mathieu, Alessandro; Scarpato, Salvatore; Rossi, Francesca W; de Paulis, Amato; Brunetta, Enrico; Ceribelli, Angela; Selmi, Carlo; Prete, Marcella; Racanelli, Vito; Vacca, Angelo; Bartoloni, Elena; Gerli, Roberto; Larosa, Maddalena; Iaccarino, Luca; Doria, Andrea. - In: ARTHRITIS & RHEUMATOLOGY. - ISSN 2326-5191. - 2020, 72:8(2020), pp. 1314-1324. [10.1002/art.41253]

Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting

Racanelli, Vito;
2020-01-01

Abstract

Objective. To investigate predictors of response, remission, low disease activity (LDA), damage 3 and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with 4 belimumab. 5 Methods. We retrospectively analysed data of a multicentre cohort of SLE patients receiving 6 intravenous belimumab. Proportion of patients achieving remission, LDA and SLE Responder 7 Index-4 (SRI-4) were evaluated. SLICC damage index (SDI) was calculated yearly. Predictors of 8 outcomes were investigated by multivariate logistic regression. 9 Results. We included 466 active SLE patients from 24 Italian centres: median (range) follow-up 10 18 (1-60) months. SRI-4 was achieved by 49.2%, 61.3%, 69.7%, 69.6% and 66.7% patients at 6, 11 12, 24, 36 and 48 months. Baseline predictors of response at 6 months were SLEDAI-2K≥10 (OR 12 3.14, 95%CI 2.033-4.860) and disease duration≤2 years (OR 1.94, 95%CI 1.078-3.473); at 12 13 months SLEDAI-2K≥10 (OR 3.48, 95%CI 2.004-6.025), SDI=0 (OR 1.74, 95%CI 1.036-2.923); 14 at 24 months SLEDAI-2K≥ 10 (OR 4.25, 95%CI 2.018-8.940), disease duration ≤2 years (OR 15 3.79, 95%CI 1.039-13.52); at 36 months SLEDAI-2K≥10 (OR 14.59, 95%CI 3.54-59.79) and 16 baseline smoking (OR 0.19, 95%CI 0.039-0.69). Patients spending≥25% follow-up in remission 17 (42.9%) or ≥ 50% in LDA (66.0%) accrued significantly less damage (p=0.046 and p=0.007). 18 Baseline SDI=0 independently predicted LDA ≥50% and remission ≥25%; the lower the baseline 19 damage, the higher the probability of remission ≥ 25%. Number of previous flares negatively 20 predicted belimumab discontinuation due to inefficacy (p= 0.009) 21 Conclusions. The early use of belimumab in patients with active SLE and low baseline damage 22 predicts favourable outcomes in a real-life setting.
2020
8
Gatto, Mariele; Saccon, Francesca; Zen, Margherita; Regola, Francesca; Fredi, Micaela; Andreoli, Laura; Tincani, Angela; Urban, Maria Letizia; Emmi, Giacomo; Ceccarelli, Fulvia; Conti, Fabrizio; Bortoluzzi, Alessandra; Govoni, Marcello; Tani, Chiara; Mosca, Marta; Ubiali, Tania; Gerosa, Maria; Bozzolo, Enrica; Canti, Valentina; Cardinaletti, Paolo; Gabrielli, Armando; Tanti, Giacomo; Gremese, Elisa; De Marchi, Ginevra; De Vita, Salvatore; Fasano, Serena; Ciccia, Francesco; Pazzola, Giulia; Salvarani, Carlo; Negrini, Simone; Puppo, Francesco; Di Matteo, Andrea; De Angelis, Rossella; Orsolini, Giovanni; Rossini, Maurizio; Faggioli, Paola; Laria, Antonella; Piga, Matteo; Mathieu, Alessandro; Scarpato, Salvatore; Rossi, Francesca W; de Paulis, Amato; Brunetta, Enrico; Ceribelli, Angela; Selmi, Carlo; Prete, Marcella; Racanelli, Vito; Vacca, Angelo; Bartoloni, Elena; Gerli, Roberto; Larosa, Maddalena; Iaccarino, Luca; Doria, Andrea
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting / Gatto, Mariele; Saccon, Francesca; Zen, Margherita; Regola, Francesca; Fredi, Micaela; Andreoli, Laura; Tincani, Angela; Urban, Maria Letizia; Emmi, Giacomo; Ceccarelli, Fulvia; Conti, Fabrizio; Bortoluzzi, Alessandra; Govoni, Marcello; Tani, Chiara; Mosca, Marta; Ubiali, Tania; Gerosa, Maria; Bozzolo, Enrica; Canti, Valentina; Cardinaletti, Paolo; Gabrielli, Armando; Tanti, Giacomo; Gremese, Elisa; De Marchi, Ginevra; De Vita, Salvatore; Fasano, Serena; Ciccia, Francesco; Pazzola, Giulia; Salvarani, Carlo; Negrini, Simone; Puppo, Francesco; Di Matteo, Andrea; De Angelis, Rossella; Orsolini, Giovanni; Rossini, Maurizio; Faggioli, Paola; Laria, Antonella; Piga, Matteo; Mathieu, Alessandro; Scarpato, Salvatore; Rossi, Francesca W; de Paulis, Amato; Brunetta, Enrico; Ceribelli, Angela; Selmi, Carlo; Prete, Marcella; Racanelli, Vito; Vacca, Angelo; Bartoloni, Elena; Gerli, Roberto; Larosa, Maddalena; Iaccarino, Luca; Doria, Andrea. - In: ARTHRITIS & RHEUMATOLOGY. - ISSN 2326-5191. - 2020, 72:8(2020), pp. 1314-1324. [10.1002/art.41253]
File in questo prodotto:
File Dimensione Formato  
Gatto M 2020.pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 447.75 kB
Formato Adobe PDF
447.75 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/387016
Citazioni
  • ???jsp.display-item.citation.pmc??? 36
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 62
social impact